Volume 24, Number 10—October 2018
Molecular Typing and Antifungal Susceptibility of Candida viswanathii, India
Highlight and copy the desired format.
|EID||Shankarnarayan SA, Rudramurthy SM, Chakrabarti A, Shaw D, Paul S, Sethuraman N, et al. Molecular Typing and Antifungal Susceptibility of Candida viswanathii, India. Emerg Infect Dis. 2018;24(10):1956-1958. https://dx.doi.org/10.3201/eid2410.180801|
|AMA||Shankarnarayan SA, Rudramurthy SM, Chakrabarti A, et al. Molecular Typing and Antifungal Susceptibility of Candida viswanathii, India. Emerging Infectious Diseases. 2018;24(10):1956-1958. doi:10.3201/eid2410.180801.|
|APA||Shankarnarayan, S. A., Rudramurthy, S. M., Chakrabarti, A., Shaw, D., Paul, S., Sethuraman, N....Ghosh, A. K. (2018). Molecular Typing and Antifungal Susceptibility of Candida viswanathii, India. Emerging Infectious Diseases, 24(10), 1956-1958. https://dx.doi.org/10.3201/eid2410.180801.|
We report invasive candidiasis caused by Candida viswanathii over 2 time periods during 2013–2015 in a tertiary care hospital in Chandigarh, India. Molecular typing revealed multiple clusters of the isolates. We detected high MICs for fluconazole in the second time period.
Invasive candidiasis is a life-threatening infection caused by various Candida species. Although C. albicans has been the predominant species causing invasive candidiasis, non-albicans Candida (NAC) species have emerged globally (1). C. viswanathii, a pathogen first isolated from the cerebrospinal fluid of a patient in 1959 (2), is rarely encountered, and only 17 cases have been reported worldwide (3). This agent has been isolated sporadically from animal and environmental sources (4–6).
We report on 23 cases of invasive candidiasis caused by C. viswanathii at a tertiary care center in Chandigarh, India, involving 7 case-patients during December 2013–April 2014 and 16 case-patients during December 2014–April 2015. In the first time period, all isolates were from blood, whereas in the second time period, the agent was isolated from pus (n = 5), blood (n = 5), cerebrospinal fluid (n = 3), and lung nodule, lung aspirate, and iliac fluid (n = 1 each).
Of the 23 patients, 16 were men and 7 were women. Six (26%) patients had neutropenia, and 18 (90%) had tuberculosis, pancreatitis, or chronic kidney disease. Eight (34.7%) patients acquired the infection after surgery. Twelve patients used indwelling devices: 3 (15%) had a central venous catheter, 4 (20%) an endotracheal tube, 3 (15%) a drainage catheter, and 2 (10%) a urinary catheter.
We screened the hospital environment and the hands of healthcare workers for a possible source of C. viswanathii infection during the second time period. We could not isolate C. viswanathii from any of those samples from a total of 46 workers and 57 different environmental sites.
Conventional methods failed to differentiate C. viswanathii and C. tropicalis. C. viswanathii assimilated sucrose and cellobiose but failed to assimilate trehalose and raffinose. C. tropicalis has a variable assimilation pattern for these sugars.
To identify the isolates, we performed matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy using MALDI-TOF MS, version 3 (Bruker Daltonik GmbH, Bremen, Germany) and sequenced the D1/D2 region of a large subunit of ribosomal DNA (7,8). Because we could not identify C. viswanathii using the MALDI-TOF MS version 3 database, we updated the database in-house by adding sequence-proved isolates of C. viswanathii. We identified the isolates with a log score of >1.8 by using the modified database. The rDNA sequence of the isolates showed 100% similarity with the type strain of C. viswanathii ATCC 22981 (GenBank accession no. NG_054835.1) except for 1 isolate (99% similarity with type strain, accession no. MF682371). The molecular phylogenetic analysis revealed that 1 isolate (B-30815) had 1 nucleotide substitution (T to C), which was 1 of the 5 substitutions we observed in C. pseudoviswanathii while comparing it with C. viswanathii (9).
Amplified fragment-length polymorphism revealed a similarity coefficient of >90% of the isolates (Technical Appendix Figure) (7). The isolates from the first time period formed 2 clusters (cluster A and B); 1 isolate from the second period was also in cluster B. Isolates of the second time period had 3 major clusters (clusters C, D, and E) and had higher MICs for fluconazole.
We performed antifungal susceptibility testing for amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, anidulafungin, and micafungin by the microbroth dilution method recommended by the Clinical and Laboratory Standards Institute (10). After incubating the plates for 24 h at 37°C, we took a visual reading to determine the MICs. The isolates of the second time period had higher MICs (MIC50 64 μg/mL, MIC90 64 μg/mL) for fluconazole compared with the isolates of the first period (MIC50 1 μg/mL, MIC90 1 μg/mL). We also recorded higher MICs (MIC50 1 μg/mL, MIC90 2 μg/mL) for voriconazole for the isolates of the second period (Table).
In conclusion, our study showed multiple clusters of C. viswanathii causing invasive infections in patients with neutropenia and chronic diseases at a single healthcare center in India. We could not trace the source of the agent. Conventional identification methods could not differentiate the isolates from those of C. tropicalis. The high MICs for fluconazole among the isolates from the second time period also raise concerns about possible antifungal resistance.
Mr. Shankarnarayan is a PhD student in the Department of Medical Microbiology, PGIMER, Chandigarh, India. His doctoral focus is on evaluating the dynamics of invasive Candida infections among hospitalized patients.
- Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:285–95.
- Viswanathan R, Randhawa HS. Candida viswanathii sp. novo isolated from a case of meningitis. Sci Cult. 1959;25:86–7.
- Randhawa HS, Mishra SK, Damodaran VN, Prakash A, Chowdhary A, Khan ZU. Pathogenicity of Candida viswanathii for normal and cortisone-treated mice. J Mycol Med. 2015;25:287–92.
- Soni P, Prasad GS, Banerjee UC. Optimization of physicochemical parameters for the enhancement of carbonyl reductase production by Candida viswanathii. Bioprocess Biosyst Eng. 2006;29:149–56.
- Soni P, Singh M, Kamble AL, Banerjee UC. Response surface optimization of the critical medium components for carbonyl reductase production by Candida viswanathii MTCC 5158. Bioresour Technol. 2007;98:829–33.
- Junior JS, Mariano AP, De Angelis DDF. Biodegradation of biodiesel/diesel blends by Candida viswanathii. Afr J Biotechnol. 2009;8:2774–8.
- Chakrabarti A, Rudramurthy SM, Kale P, Hariprasath P, Dhaliwal M, Singhi S, et al. Epidemiological study of a large cluster of fungaemia cases due to Kodamaea ohmeri in an Indian tertiary care centre. Clin Microbiol Infect. 2014;20:O83–9.
- Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A, Jillwin TJ, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. Clin Microbiol Infect. 2015;21:372–8.
- Ren YC, Xu LL, Zhang L, Hui FL. Candida baotianmanensis sp. nov. and Candida pseudoviswanathii sp. nov., two ascosporic yeast species isolated from the gut of beetles. Int J Syst Evol Microbiol. 2015;65:3580–5.
- Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd edition, approved standard (M27–A3). Wayne (PA): The Institute; 2008.
TableCite This Article
Original Publication Date: 9/4/2018
- Page created: September 17, 2018
- Page last updated: September 17, 2018
- Page last reviewed: September 17, 2018
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)